Cyfuse Biomedical K.K. (TYO:4892)

Cyfuse Biomedical K.K. Revenue

Cyfuse Biomedical K.K. had revenue of 76.00M JPY in the quarter ending June 30, 2026, with 1,420.00% growth. This brings the company's total for the last twelve months to 305.00M, up 369.23% year-over-year. In the year 2025, Cyfuse Biomedical K.K. had annual revenue of 230.00M with 325.93% growth. That makes Cyfuse Biomedical K.K. the 42,460th largest company in the world by revenue and 3,850th in Japan.

• Revenue (ttm): 305.00M
• Revenue Growth: +369.23%
• P/S Ratio: 18.46
• Revenue / Employee: 13.26M
• Employees: 23
• Market Cap: 5.63B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

• Regenerative Medicine 36.68M 67.4%
• Device 13.22M 24.3%
• Drug Discovery Support 4.55M 8.3%

By Geography

• Japan 54.15M 99.5%
• United States 295.00K 0.5%

Fiscal year ended Dec 31, 2024 See the full Cyfuse Biomedical K.K. breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	230.00M	176.00M	325.93%
Dec 31, 2024	54.00M	-7.00M	-11.48%
Dec 31, 2023	61.00M	-313.00M	-83.69%
Dec 31, 2022	374.00M	-334.00M	-47.18%
Dec 31, 2021	708.00M	571.00M	416.79%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 25, 2026

Data Sources Report a data error